Titratable dosing in moderate to severe asthmatics

Study identifier:SD-039-0728

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 52 wk Randomized, doubleblind, single dummy, parallel group multicenter Phase 3 study comparing the long term safety of Symbicort pMDI 4x160/4.5mcg bid to SymbicortpMDI 2x160/4.5mcg bid & budesonide HFA pMDI 4x160mcg bid in adult and adolescent subjects with asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

budesonide/formoterol, Symbicort pMDI + budesonide HFA pMDI

Sex

All

Actual Enrollment

570

Study type

Interventional

Age

12 Years +

Date

Study Start Date: 01 Aug 2003
Primary Completion Date: -
Study Completion Date: 01 Jan 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria